OSAKA – Nippon Boehringer Ingelheim Co. said Tuesday its consolidated sales rose 4.9 percent in 2000 from the previous year to 75.1 billion yen, the biggest since its establishment in 1961.
The Japanese subsidiary of German pharmaceutical maker Boehringer Ingelheim GmbH, attributed the high performance to a 19.9 percent surge in sales of an antiallergenic agent to 25.4 billion yen and a 6.4 percent increase in demand for a sleeping aid, to 13.5 billion yen.
For this year, the company projects group sales will top 82 billion yen, boosted by a nonsteroid, anti-inflammatory pain reliever launched in February.
The figures were announced in line with the company’s reporting to its parent for its fiscal yearend on Dec. 31.
Profit and other data of the Japanese subsidiary have yet to be released as it closed its books March 31.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.